Welcome to LookChem.com Sign In|Join Free

CAS

  • or

135729-56-5

Post Buying Request

135729-56-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

135729-56-5 Usage

Uses

Palonosetron can be used to Anti-emetic; antinauseant.

Brand name

Aloxi (Helsinn).

Check Digit Verification of cas no

The CAS Registry Mumber 135729-56-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,7,2 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 135729-56:
(8*1)+(7*3)+(6*5)+(5*7)+(4*2)+(3*9)+(2*5)+(1*6)=145
145 % 10 = 5
So 135729-56-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1

135729-56-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Palonosetron

1.2 Other means of identification

Product number -
Other names Palonosteron

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:135729-56-5 SDS

135729-56-5Related news

Scientific ArticleThe effect of Palonosetron (cas 135729-56-5) on rocuronium-induced withdrawal movementO efeito de Palonosetron (cas 135729-56-5) sobre o movimento de retração induzido por rocurônio08/19/2019

BackgroundRocuronium causes pain and withdrawal movement during induction of anesthesia. In this study, palonosetron was investigated to have analgesic effect on the reduction of rocuronium-induced withdrawal movement.detailed

Development and evaluation of Palonosetron (cas 135729-56-5) loaded mucoadhesive buccal films08/17/2019

Clinical potential of palonosetron in oral therapy is mainly limited by low permeability. The purpose of this study was to develop oral mucoadhesive film with palonosetron and evaluate its prospective for buccal delivery. Films were prepared by solvent casting method using proloc 15 and eudragit...detailed

Comparison Of Ondansetron, Tropisetron And Palonosetron (cas 135729-56-5) For The Prevention Of Postoperative Nausea And Vomiting After Middle Ear Surgery08/16/2019

Objective: Postoperative nausea and vomiting (PONV) are two of the most frequent adverse effects of anesthesia. PONV prolongs hospital stays and also delays the recovery of patients. In this study, the effects of ondansetron, tropisetron and palonosetron on PONV in patients who had undergone mid...detailed

135729-56-5Relevant articles and documents

Total synthesis of the 5-HT3 receptor antagonist palonosetron

Kowalczyk, Bruce A.,Dvorak, Charles A.

, p. 816 - 818 (1996)

A short and efficient synthetic route to the 5-HT3 receptor antagonists 1 and 2 (palonosetron) was developed. The novel adjustment of the oxidation states at the necessary centers of imide 7 was accomplished by hydrogenation, selective sodium borohydride reduction, and dehydration to yield 1. The sodium borohydride reduction of imide 8 was selective for the C-3 carbonyl versus the C-1 carbonyl next to the aromatic ring to give the hydroxy compound 9. It was essential to keep the sodium borohydride reduction free of oxygen, or diols 10a and 10b were formed as significant byproducts.

Process for the Preparation of Substantially Pure Palonosetron and its Acid Salts

-

Page/Page column 5, (2011/02/18)

This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent.(b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction.(c) Finally, converting the resulting diastereomeric palonosetron (VIII) or its hydrochloride (VIIIa) substantially free from intermediate (II) or (IIa) to the desired palonosetron hydrochloride (I) in substantially pure form via selective crystallization from a suitable single or mixture of organic solvents.

Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein

-

, (2008/06/13)

This invention relates to processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one, particularly 2-(1-azabicyclo[2.2.2]oct-3S-yl)-2, 3,3aS,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one, and to intermediates useful in such processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 135729-56-5